![[Analysis 1.1]](/images/14651858/forrest_default.gif) | Analysis 1.1. Comparison 1 Artemether-lumefantrine (4 doses) versus sulfadoxine-pyrimethamine, Outcome 1 Total failure by day 14. |
![[Analysis 1.2]](/images/14651858/forrest_default.gif) | Analysis 1.2. Comparison 1 Artemether-lumefantrine (4 doses) versus sulfadoxine-pyrimethamine, Outcome 2 Total failure by day 14 (excluding new infections). |
![[Analysis 1.3]](/images/14651858/forrest_default.gif) | Analysis 1.3. Comparison 1 Artemether-lumefantrine (4 doses) versus sulfadoxine-pyrimethamine, Outcome 3 Gametocyte carriage by day 4. |
![[Analysis 1.4]](/images/14651858/forrest_default.gif) | Analysis 1.4. Comparison 1 Artemether-lumefantrine (4 doses) versus sulfadoxine-pyrimethamine, Outcome 4 Gametocyte carriage by day 15. |
![[Analysis 2.1]](/images/14651858/forrest_default.gif) | Analysis 2.1. Comparison 2 Artemether-lumefantrine (4 doses) versus mefloquine, Outcome 1 Total failure by day 28. |
![[Analysis 2.2]](/images/14651858/forrest_default.gif) | Analysis 2.2. Comparison 2 Artemether-lumefantrine (4 doses) versus mefloquine, Outcome 2 Gametocyte carriage within the first 72 h. |
![[Analysis 3.1]](/images/14651858/forrest_default.gif) | Analysis 3.1. Comparison 3 Artemether-lumefantrine (4 doses) versus halofantrine, Outcome 1 Total failure by day 28. |
![[Analysis 3.2]](/images/14651858/forrest_default.gif) | Analysis 3.2. Comparison 3 Artemether-lumefantrine (4 doses) versus halofantrine, Outcome 2 Gametocyte carriage within the first 72 h. |
![[Analysis 4.1]](/images/14651858/forrest_default.gif) | Analysis 4.1. Comparison 4 Artemether-lumefantrine (4 doses) versus chloroquine, Outcome 1 Total failure by day 28. |
![[Analysis 4.2]](/images/14651858/forrest_default.gif) | Analysis 4.2. Comparison 4 Artemether-lumefantrine (4 doses) versus chloroquine, Outcome 2 Gametocyte carriage within the first 72 h. |
![[Analysis 5.1]](/images/14651858/forrest_default.gif) | Analysis 5.1. Comparison 5 Artemether-lumefantrine versus mefloquine plus artesunate, Outcome 1 Total failure by day 28. |
![[Analysis 5.2]](/images/14651858/forrest_default.gif) | Analysis 5.2. Comparison 5 Artemether-lumefantrine versus mefloquine plus artesunate, Outcome 2 Total failure by day 28 (excluding new infections). |
![[Analysis 5.3]](/images/14651858/forrest_default.gif) | Analysis 5.3. Comparison 5 Artemether-lumefantrine versus mefloquine plus artesunate, Outcome 3 Total failure by day 63. |
![[Analysis 5.4]](/images/14651858/forrest_default.gif) | Analysis 5.4. Comparison 5 Artemether-lumefantrine versus mefloquine plus artesunate, Outcome 4 Gametocyte carriage within the first 72 h. |
![[Analysis 6.1]](/images/14651858/forrest_default.gif) | Analysis 6.1. Comparison 6 Artemether-lumefantrine (4 doses) versus artemether-lumefantrine (6 doses), Outcome 1 Total failure by day 28. |